EGFR and non-small cell lung carcinoma: In this study, A549 and H1299-CD151 overexpressed cells and control cells were treated with either gefitinib or lapatinib, results shown that there were obvious decreases in p-EGFR, p-HerB2, p-FAK, p-AKT and p-Erk levels in the control group over that in CD151 overexpressed cells, so we speculated CD151 knockdown may affect the sensitivity of NSCLC in response to anti-cancer drugs.